What topics does this cannabis study cover?

This study covers research on: CBD, Cancer, Inflammation, Endocannabinoid.

Targeting melanoma cell membranes through fat metabolism

Q: What did this research study find?

*CBD* (5 µM) and *CBG* (1 µM) **altered melanoma cell membrane structure**, affecting *lipid rafts* and surface charge density, which may represent a novel anticancer target

Q: Where was this research published?

Published in Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie on January 12, 2026.

Phytocannabinoids influence phospholipid metabolism of melanoma cells: Modulation of in vitro effects of the UVA irradiation.

Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie • January 12, 2026 • Highly Relevant

🤖

AI Summary

This laboratory study investigated how cannabidiol (CBD) and cannabigerol (CBG) affect the cell membranes and fat metabolism of melanoma cells, particularly when combined with UVA radiation therapy. Researchers treated aggressive SK-MEL-5 melanoma cells with 5 µM CBD and 1 µM CBG for 24 hours, both alone and after UVA light exposure, then analyzed changes to cell membrane structure, fat molecules, and inflammatory signaling pathways. The phytocannabinoids partially counteracted stress-induced changes in the cell membrane, including alterations to polyunsaturated fatty acids (PUFAs) and membrane structures called lipid rafts, which could represent a new target for melanoma treatment.

The combination of CBD and CBG produced particularly interesting effects on cellular signaling molecules. The phytocannabinoids significantly increased levels of 2-AG, an endocannabinoid produced naturally in the body, while reducing pro-inflammatory eicosanoids when used together. This occurred through changes in enzyme activity (PLA2, COX-1/2, and LOX-5) that break down membrane fats. While UVA radiation increased expression of cannabinoid receptors (CB1, CB2, TRPV1, and PPARγ) in melanoma cells, the CBD/CBG combination reduced their expression, suggesting the phytocannabinoids may help normalize abnormal receptor signaling in cancer cells.

These findings suggest that CBD and CBG may have potential as complementary therapies in melanoma treatment by modifying how cancer cells process fats and respond to inflammation. The ability of these phytocannabinoids to alter membrane structure and reduce inflammatory signaling pathways offers new insights into how cannabis compounds might support conventional cancer treatments, though human clinical trials would be needed to confirm therapeutic benefits.

💡 Key Findings

CBD (5 µM) and CBG (1 µM) altered melanoma cell membrane structure, affecting lipid rafts and surface charge density, which may represent a novel anticancer target

Good

75%

The CBD/CBG combination reduced pro-inflammatory eicosanoids while increasing endocannabinoid 2-AG levels by modifying fat-processing enzyme activity

High

80%

Phytocannabinoids reduced expression of cannabinoid receptors (CB1, CB2, TRPV1, PPARγ) that were elevated by UVA radiation in melanoma cells

Good

75%

CBD and CBG partially enhanced UVA-induced decreases in free PUFAs, suggesting potential synergy with radiation-based melanoma treatments

Good

70%

📄 Original Abstract

The high metastatic potential of melanoma and its poor prognosis in advanced stages motivate the search for innovative therapeutic approaches. Therefore, this study aimed to assess the effects of phytocannabinoids (cannabidiol-CBD, and cannabigerol-CBG) on the structure and function of the melanoma cell membrane, phospholipid metabolism, and the respective metabolites generated in ROS- and enzyme-dependent reactions. Biochemical and physicochemical parameters were analyzed in melanoma cells (SK-MEL-5) cultured for 24 h with CBD (5 µM), CBG (1 µM), and their combination applied either alone or after UVA irradiation (365 nm) at a dose of 18 J/cm². Phytocannabinoids have been shown to partially counteract changes in the levels of cell membrane components, including phospholipid polyunsaturated fatty acids (PUFAs) and sialic acid, consequently affecting surface charge density and lipid rafts, which may be a potential target for anticancer therapy. Furthermore, by changing the activity of lipolytic enzymes (PLA2/COX1/2/LOX-5), phytocannabinoids partially enhanced the UVA-induced decrease in free PUFAs. Consequently, the levels of lipid mediators, including endocannabinoids and eicosanoids, were altered. The use of phytocannabinoids led to a significant increase in 2-AG levels, while the combined action of CBD/CBG reduced the levels of pro-inflammatory eicosanoids. UVA radiation increased the expression of G-protein-coupled receptors in melanoma cells (CB1/2/TRPV1/PPARγ), while the combined use of CBD/CBG reduced their expression. Therefore, the results have shown that CBD and CBG modulate the metabolism of phospholipids and PUFAs by altering the functions of melanoma cell membranes, potentially offering options for the use of these phytocannabinoids in the integrative biomedicine treatment of melanoma.

Paper Type

📄 Research

Publication

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: January 12, 2026
PMID: 41529510
DOI: 10.1016/j.biopha.2026.119003

Authors (8)

Michał Biernacki Department of Analytical Chemistry, Medical University of Białystok, Mickiewicza 2D, Białystok 15-222, Poland. Electronic address: michal.biernacki@umb.edu.pl.
Szymon Sękowski Laboratory of Molecular Biophysics, Department of Microbiology and Biotechnology, Faculty of Biology, University in Białystok, Ciołkowskiego 1J, Białystok 15-245, Poland. Electronic address: s.sekowski@uwb.edu.pl.
Izabela Dobrzyńska Laboratory of Bioanalysis, Faculty of Chemistry, University in Białystok, Ciołkowskiego 1K, Białystok 15-245, Poland. Electronic address: izadob@uwb.edu.pl.
Ewa Olchowik-Grabarek Laboratory of Molecular Biophysics, Department of Microbiology and Biotechnology, Faculty of Biology, University in Białystok, Ciołkowskiego 1J, Białystok 15-245, Poland. Electronic address: ewaolch@uwb.edu.pl.
Neven Zarkovic Ruder Boskovic Institute, Div. Molecular Medicine Laboratory for Oxidative Stress, Zagreb, Croatia.
+3 more authors